An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder - PubMed (original) (raw)
Clinical Trial
An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder
L H Taylor et al. J Clin Psychiatry. 2000 Aug.
Abstract
Background: Recent interest in and evidence for the efficacy of St. John's wort (Hypericum perforatum) for the treatment of mild-to-moderate depression has led to speculation about its efficacy in other disorders. Hypericum's mechanism of action is postulated to be via inhibition of the synaptosomal uptake of serotonin. As such, there is a suggestion that Hypericum may be effective for obsessive-compulsive disorder (OCD).
Method: Twelve subjects were evaluated with a primary DSM-IV diagnosis of OCD of at least 12 months' duration. Treatment lasted for 12 weeks, with a fixed dose of 450 mg of 0.3% hypericin (a psychoactive compound in Hypericum) twice daily (extended-release formulation). Weekly evaluations were conducted with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the Patient Global Impressions of Improvement Scale, and the Clinical Global Impressions of Improvement scale (CGI) and monthly evaluation with the Hamilton Rating Scale for Depression.
Results: A significant change from baseline to endpoint was found, with a mean Y-BOCS change of 7.4 points (p = .001). Significant change occurred at 1 week (p = .020) and continued to increase throughout the trial. At endpoint, 5 (42%) of 12 were rated "much" or "very much improved" on the clinician-rated CGI, 6 (50%) were "minimally improved," and 1 (8%) had "no change." The most common side effects reported were diarrhea (N = 3) and restless sleep (N = 2).
Conclusion: Significant improvement was found with Hypericum, with a drop-in Y-BOCS score similar to that found in clinical trials. The fact that a significant change was found as early as 1 week into treatment suggests a possible initial placebo response, although improvement grew larger over time. Results warrant a placebo-controlled study of Hypericum in OCD.
Similar articles
- St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study.
Kobak KA, Taylor LV, Bystritsky A, Kohlenberg CJ, Greist JH, Tucker P, Warner G, Futterer R, Vapnik T. Kobak KA, et al. Int Clin Psychopharmacol. 2005 Nov;20(6):299-304. doi: 10.1097/00004850-200511000-00003. Int Clin Psychopharmacol. 2005. PMID: 16192837 Clinical Trial. - Effectiveness of St John's wort in major depression: a randomized controlled trial.
Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U. Shelton RC, et al. JAMA. 2001 Apr 18;285(15):1978-86. doi: 10.1001/jama.285.15.1978. JAMA. 2001. PMID: 11308434 Clinical Trial. - Comparison of St John's wort and imipramine for treating depression: randomised controlled trial.
Woelk H. Woelk H. BMJ. 2000 Sep 2;321(7260):536-9. doi: 10.1136/bmj.321.7260.536. BMJ. 2000. PMID: 10968813 Free PMC article. Clinical Trial. - St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties.
Barnes J, Anderson LA, Phillipson JD. Barnes J, et al. J Pharm Pharmacol. 2001 May;53(5):583-600. doi: 10.1211/0022357011775910. J Pharm Pharmacol. 2001. PMID: 11370698 Review. - St John's wort for depression.
Linde K, Mulrow CD. Linde K, et al. Cochrane Database Syst Rev. 2000;(2):CD000448. doi: 10.1002/14651858.CD000448. Cochrane Database Syst Rev. 2000. PMID: 10796719 Updated. Review.
Cited by
- Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University; Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR. Katzman MA, et al. BMC Psychiatry. 2014;14 Suppl 1(Suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. BMC Psychiatry. 2014. PMID: 25081580 Free PMC article. Review. - St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?
Kholghi G, Arjmandi-Rad S, Zarrindast MR, Vaseghi S. Kholghi G, et al. Naunyn Schmiedebergs Arch Pharmacol. 2022 Jun;395(6):629-642. doi: 10.1007/s00210-022-02229-z. Epub 2022 Mar 16. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35294606 Review. - Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.
Sarris J, McIntyre E, Camfield DA. Sarris J, et al. CNS Drugs. 2013 Apr;27(4):301-19. doi: 10.1007/s40263-013-0059-9. CNS Drugs. 2013. PMID: 23653088 Review. - Pharmacological management of treatment-resistant obsessive-compulsive disorder.
Abudy A, Juven-Wetzler A, Zohar J. Abudy A, et al. CNS Drugs. 2011 Jul;25(7):585-96. doi: 10.2165/11587860-000000000-00000. CNS Drugs. 2011. PMID: 21699270 Review. - Hypericum perforatum: Traditional uses, clinical trials, and drug interactions.
Nobakht SZ, Akaberi M, Mohammadpour AH, Tafazoli Moghadam A, Emami SA. Nobakht SZ, et al. Iran J Basic Med Sci. 2022 Sep;25(9):1045-1058. doi: 10.22038/IJBMS.2022.65112.14338. Iran J Basic Med Sci. 2022. PMID: 36246064 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials